Electromed Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Electromed te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.0%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	13 Nov 2024

Recente toekomstige groei-updates

Recent updates

What Percentage Of Electromed, Inc. (NYSEMKT:ELMD) Shares Do Insiders Own?

Mar 07

Is Electromed, Inc.'s (NYSEMKT:ELMD) Latest Stock Performance A Reflection Of Its Financial Health?

Feb 17

Electromed, Inc.'s (NYSEMKT:ELMD) Intrinsic Value Is Potentially 90% Above Its Share Price

Dec 16

Announcing: Electromed (NYSEMKT:ELMD) Stock Soared An Exciting 405% In The Last Five Years

Dec 04

How Is Electromed's (NYSEMKT:ELMD) CEO Paid Relative To Peers?

Nov 22

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Electromed onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NYSEAM:ELMD - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2025	62	7	N/A	N/A	1
9/30/2024	57	6	11	12	N/A
6/30/2024	55	5	9	9	N/A
3/31/2024	53	4	5	6	N/A
12/31/2023	52	4	4	5	N/A
9/30/2023	50	3	1	3	N/A
6/30/2023	48	3	0	1	N/A
3/31/2023	46	3	-2	0	N/A
12/31/2022	44	2	-3	-1	N/A
9/30/2022	42	2	-3	-2	N/A
6/30/2022	42	2	-2	-1	N/A
3/31/2022	40	2	0	1	N/A
12/31/2021	39	2	1	1	N/A
9/30/2021	38	2	1	2	N/A
6/30/2021	36	2	3	3	N/A
3/31/2021	33	3	3	4	N/A
12/31/2020	33	4	3	4	N/A
9/30/2020	32	4	4	4	N/A
6/30/2020	32	4	3	4	N/A
3/31/2020	34	4	2	4	N/A
12/31/2019	33	4	2	4	N/A
9/30/2019	32	3	1	3	N/A
6/30/2019	31	2	1	3	N/A
3/31/2019	31	2	1	2	N/A
12/31/2018	30	2	1	2	N/A
9/30/2018	29	2	2	2	N/A
6/30/2018	28	2	N/A	2	N/A
3/31/2018	28	2	N/A	2	N/A
12/31/2017	27	2	N/A	3	N/A
9/30/2017	27	2	N/A	3	N/A
6/30/2017	26	2	N/A	1	N/A
3/31/2017	24	2	N/A	1	N/A
12/31/2016	24	1	N/A	1	N/A
9/30/2016	23	2	N/A	1	N/A
6/30/2016	23	2	N/A	2	N/A
3/31/2016	22	2	N/A	3	N/A
12/31/2015	21	2	N/A	3	N/A
9/30/2015	20	1	N/A	2	N/A
6/30/2015	19	1	N/A	3	N/A
3/31/2015	19	1	N/A	3	N/A
12/31/2014	18	0	N/A	2	N/A
9/30/2014	17	-1	N/A	2	N/A
6/30/2014	15	-1	N/A	2	N/A
3/31/2014	15	-2	N/A	2	N/A
12/31/2013	14	-1	N/A	2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van ELMD boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van ELMD naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van ELMD naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van ELMD naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van ELMD naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ELMD naar verwachting over 3 jaar hoog zal zijn

Electromed Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 25%, revenue upgraded

Price target increased to US$16.75

Consensus forecasts updated

Electromed, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter Ended June 30, 2021

Consensus forecasts updated

Price target increased to US$18.00

Recent updates

Chairman recently sold US$4.2m worth of stock

Chairman notifies of intention to sell stock

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 18%

Electromed, Inc. to Report Q1, 2025 Results on Nov 12, 2024

President exercised options and sold US$739k worth of stock

Electromed, Inc., Annual General Meeting, Nov 15, 2024

Investor sentiment improves as stock rises 18%

Electromed, Inc. (NYSEAM:ELMD) announces an Equity Buyback for $5 million worth of its shares.

Full year 2024 earnings: EPS exceeds analyst expectations

Electromed, Inc. to Report Q4, 2024 Results on Aug 27, 2024

Investor sentiment deteriorates as stock falls 17%

Third quarter 2024 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Electromed, Inc. to Report Q3, 2024 Results on May 07, 2024

Investor sentiment improves as stock rises 16%

President recently bought US$137k worth of stock

Investor sentiment improves as stock rises 48%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. to Report Q2, 2024 Results on Feb 13, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Electromed, Inc. Announces Launch of SmartVest Clearway Airway Clearance System

Electromed, Inc. to Report Q1, 2024 Results on Nov 07, 2023

Electromed, Inc., Annual General Meeting, Nov 10, 2023

Consensus EPS estimates fall by 25%, revenue upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Electromed, Inc. to Report Q4, 2023 Results on Aug 22, 2023

Electromed, Inc. Announces Appointment of Jim Cunniff as Its New President and Board of Director, Effective July 1, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

CEO, President & Director exercised options and sold US$245k worth of stock

Investor sentiment improves as stock rises 15%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. Announces Retirement of Kathleen Skarvan as Chief Executive Officer, Effective on or Around July 1, 2023

Electromed, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Electromed, Inc. Announces U.S. Food and Drug Administration 510(K) Clearance of Fifth Generation Hfcwo Airway Clearance Generator

Price target increased to US$16.75

First quarter 2023 earnings: EPS misses analyst expectations

Electromed, Inc. to Report Q1, 2023 Results on Nov 08, 2022

Electromed, Inc. Appoints Brad Nagel as Chief Financial Officer, Effective November 14, 2022

Electromed, Inc., Annual General Meeting, Nov 11, 2022

CEO, President & Director exercised options and sold US$59k worth of stock

Investor sentiment improved over the past week

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Electromed, Inc. to Report Q4, 2022 Results on Aug 23, 2022

High number of new directors

Electromed, Inc. Announces Election of Andrew Summers as Additional Independent Director

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. Announces Executive Changes

Electromed, Inc. to Report Q3, 2022 Results on May 10, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

First quarter 2022 earnings released: EPS US$0.051 (vs US$0.063 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$0.28 (vs US$0.49 in FY 2020)

Electromed, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter Ended June 30, 2021

Summers Value Fund Engages in Discussion with Electromed Shareholders

Electromed, Inc.(NYSEAM:ELMD) dropped from Russell 3000 Growth Index

Electromed, Inc. (NYSEAM:ELMD) announces an Equity Buyback for $3 million worth of its shares.

Consensus forecasts updated

Third quarter 2021 earnings released: EPS US$0.026 (vs US$0.078 in 3Q 2020)

Price target increased to US$18.00

What Percentage Of Electromed, Inc. (NYSEMKT:ELMD) Shares Do Insiders Own?

Is Electromed, Inc.'s (NYSEMKT:ELMD) Latest Stock Performance A Reflection Of Its Financial Health?

Analysts increase EPS estimates to US$0.34

Revenue and earnings beat expectations

Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.14 in 2Q 2020)

New 90-day high: US$10.76

Should You Be Impressed By Electromed's (NYSEMKT:ELMD) Returns on Capital?

Electromed, Inc. to Report Q2, 2021 Results on Feb 09, 2021